William V. Tamborlane, MD, Receives American Diabetes Association’s 2017 Outstanding Achievement in Clinical Diabetes Research Award
May 12, 2017
The American Diabetes Association® (Association) will present the 2017 Outstanding Achievement in Clinical Diabetes Research Award to William V. Tamborlane, MD. This award recognizes exceptional contributions in patient-oriented or clinical outcomes research that have had a significant impact on diabetes prevention and treatment. Dr. Tamborlane will be recognized with this honor during the Association’s 77th Scientific Sessions, June 9-13, 2016, at the San Diego Convention Center.
Currently Professor and Chief of Pediatric Endocrinology at Yale University and Deputy Director of the Yale Center for Clinical Investigation, Dr. Tamborlane is renowned for patient-oriented research. Employing a wide range of innovative and sophisticated techniques, his efforts have advanced clinical trial methodologies, behavioral interventions and epidemiologic cohort studies in both type 1 and type 2 diabetes. Among Dr. Tamborlane’s major accomplishments are pioneering studies in the development of insulin pump therapy; demonstration that intensive diabetes treatment impairs counterregulatory responses to hypoglycemia; development of novel behavioral interventions to improve outcomes for adolescents with type 1 diabetes; and the development of the first registry of youth with type 2 diabetes in the U.S.
“Congratulations and thank you to Dr. Tamborlane for his remarkable research contributions that have not only shaped the way we approach diabetes care, but have also given us a clearer understanding of how young people with diabetes think and better tools to help them manage the disease,” said the Association’s President of Medicine and Science Alvin C. Powers, MD. “Your work has led to outstanding advancements in diabetes treatment and touched countless lives in the process.”
Dr. Tamborlane has held leadership roles in several multicenter diabetes trials and studies, including the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study, the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study, JDRF’s Continuous Glucose Monitoring Study Group, Pediatric Diabetes Consortium T2D Clinical Trials Network and the Glycemia Reduction Approaches in Diabetes (GRADE) study. With more than 850 publications and a long-standing commitment to mentoring students, fellows and junior faculty, Dr. Tamborlane continues to shape the future in clinical diabetes investigation.
The American Diabetes Association’s 77th Scientific Sessions, to be held June 9-13, 2017, at the San Diego Convention Center, is the world’s largest scientific meeting focused on diabetes research, prevention and care. During the five-day meeting, health care professionals have exclusive access to more than 2,500 original research presentations, participate in provocative and engaging exchanges with leading diabetes experts, and can earn Continuing Medical Education (CME) or Continuing Education (CE) credits for educational sessions. The program is grouped into eight interest areas: Acute and Chronic Complications; Behavioral Medicine, Clinical Nutrition, Education and Exercise; Clinical Diabetes/Therapeutics; Epidemiology/Genetics; Immunology/Transplantation; Insulin Action/Molecular Metabolism; Integrated Physiology/Obesity; and Islet Biology/Insulin Secretion. Brenda Montgomery, RN, MSHS, CDE, President of Health Care and Education¹, will deliver her address on Saturday, June 10, and Alvin C. Powers, MD, President of Medicine and Science, will present his address on Sunday, June 11. Eight abstracts were selected by the Scientific Sessions Meeting Planning Committee to be presented on Tuesday, June 13, in the President’s Oral Session. These abstracts represent important research being conducted in the field of diabetes today. In total, the 2017 Scientific Sessions includes 378 abstracts in 49 oral sessions; 2,152 poster presentations including 50 moderated poster discussions; and 360 published-only abstracts.
About the American Diabetes Association
Nearly half of American adults have diabetes or prediabetes; more than 30 million adults and children have diabetes; and every 21 seconds, another individual is diagnosed with diabetes in the U.S. Founded in 1940, the American Diabetes Association (ADA) is the nation’s leading voluntary health organization whose mission is to prevent and cure diabetes, and to improve the lives of all people affected by diabetes. The ADA drives discovery by funding research to treat, manage and prevent all types of diabetes, as well as to search for cures; raises voice to the urgency of the diabetes epidemic; and works to safeguard policies and programs that protect people with diabetes. In addition, the ADA supports people living with diabetes, those at risk of developing diabetes, and the health care professionals who serve them through information and programs that can improve health outcomes and quality of life. For more information, please call the ADA at 1-800-DIABETES (1-800-342-2383) or visit diabetes.org. Information from both of these sources is available in English and Spanish. Find us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn)
1 Disclosures for Brenda Montgomery. Employer: AstraZeneca Pharmaceuticals. Montgomery's role as President, Health Care & Education of the American Diabetes Association (Association) is a voluntary position to which she was elected by the members of the Association in 2015. She continues to recuse herself from any and all discussions, decisions or votes that have or could be perceived as having a conflict of interest with her employer.